CIK 0001816736 · Large accelerated filer
Disc Medicine, Inc.
Sign in to watch- Ticker
- IRON
- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- FY end
- Dec 31
- Entity type
- operating
- EIN
- 851612845
- Phone
- (617) 674-9274
- Business address
- 321 ARSENAL STREET, SUITE 101, WATERTOWN, MA, 02472
- Former names
- Gemini Therapeutics, Inc. /DE, FS Development Corp.
- Open-market buys, last 90 days
- $0
- in 0 filings
- Open-market sales, last 90 days
- $14,489,047
- in 7 filings, $12.6M under 10b5-1 plans
Net −$14,489,047. Shares bought or sold at a price by officers, directors and 10% owners (Form 4 codes P and S). Grants, option exercises and tax withholding aren't counted.
Who's trading
90 days
Reading 100 more Form 4s from the SEC; this list fills in as they're read.
| Date | Insider | Transaction | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| 2026-06-18 | Quisel John D Chief Executive Officer | Sale 10b5-1 | −9,522 | $70.70 | $673K | 227,615 |
| 2026-06-18 | Quisel John D Chief Executive Officer | Sale 10b5-1 | −1,551 | $71.61 | $111K | 226,064 |
| 2026-06-18 | Quisel John D Chief Executive Officer | Option exercise · Stock Option (Right to Buy) 10b5-1 | −34,000 | 41,375 | ||
| 2026-06-18 | White William Richard Director | Grant or award · Stock Option (Right to Buy) | +6,212 | 6,212 | ||
| 2026-06-18 | Ratcliffe Liam Director | Grant or award · Stock Option (Right to Buy) | +6,212 | 6,212 | ||
| 2026-06-18 | Nicholson Donald William Director | Grant or award · Stock Option (Right to Buy) | +6,212 | 6,212 | ||
| 2026-06-18 | GEMAYEL GEORGES Director | Grant or award · Stock Option (Right to Buy) | +6,212 | 6,212 | ||
| 2026-06-18 | Chin Mark Director | Grant or award · Stock Option (Right to Buy) | +6,212 | 6,212 | ||
| 2026-06-18 | Bitterman Kevin Director | Grant or award · Stock Option (Right to Buy) | +6,212 | 6,212 | ||
| 2026-06-18 | AHMED NADIM Director | Grant or award · Stock Option (Right to Buy) | +5,176 | 5,176 | ||
| 2026-06-16 | Yu Jonathan Yen-Wen Chief Operating Officer | Option exercise 10b5-1 | +5,261 | $9.86 | $52K | 59,585 |
| 2026-06-16 | Yu Jonathan Yen-Wen Chief Operating Officer | Option exercise 10b5-1 | +13,351 | $9.86 | $132K | 72,936 |
| 2026-06-16 | Yu Jonathan Yen-Wen Chief Operating Officer | Sale 10b5-1 | −11,651 | $68.76 | $801K | 61,285 |
| 2026-06-16 | Yu Jonathan Yen-Wen Chief Operating Officer | Sale 10b5-1 | −6,961 | $69.92 | $487K | 54,324 |
| 2026-06-16 | Yu Jonathan Yen-Wen Chief Operating Officer | Option exercise · Stock Option (Right to Buy) 10b5-1 | −5,261 | 1,753 | ||
| 2026-06-16 | Yu Jonathan Yen-Wen Chief Operating Officer | Option exercise · Stock Option (Right to Buy) 10b5-1 | −13,351 | 31,951 | ||
| 2026-04-14 | Franchi Jean M. Chief Financial Officer | Sale 10b5-1 | −6,257 | $69.24 | $433K | 64,333 |
| 2026-04-13 | Savage William Jacob Chief Medical Officer | Sale 10b5-1 | −3,531 | $66.12 | $233K | 81,680 |
| 2026-04-13 | Savage William Jacob Chief Medical Officer | Sale 10b5-1 | −2,200 | $66.81 | $147K | 79,480 |
| 2026-04-13 | Franchi Jean M. Chief Financial Officer | Sale 10b5-1 | −400 | $69.00 | $28K | 70,590 |
Page 5 of 17 · 337 trades